<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982367</url>
  </required_header>
  <id_info>
    <org_study_id>Acoart SCB SFA</org_study_id>
    <nct_id>NCT04982367</nct_id>
  </id_info>
  <brief_title>Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety Between Sirolimus Coated Balloon Catheter and Paclitaxel Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized trial designed to compare the efficacy and safety of Sirolimus&#xD;
      coated balloon (SCB) versus paclitaxel coated balloon (DCB) in the treatment of&#xD;
      femoropopliteal artery stenosis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary patency rate of target lesion at 12 months post-procedure</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Defined as freedom from clinically driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of device success</measure>
    <time_frame>immediate post-procedure</time_frame>
    <description>Defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically driven target lesion revascularization (CD-TLR) at 12 months post-procedure</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Defined as any reintervention at the target lesion due to symptoms or the following index: drop of ABI &gt;20% or ABI &gt;0.15 compared to the post-procedure ABI during 12 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Rutherford class from baseline</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Defined as change in target limb Rutherford class from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of ankle-brachial index (ABI) from baseline</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Defined as change of target limb ABI from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite safety endpoint</measure>
    <time_frame>30 days post-procedure</time_frame>
    <description>Defined a composite rate of device-related or procedure-related death, major target limb amputation (above-the-ankle amputation), clinically driven target lesion revascularization (CD-TLR) or target lesion thrombotic events through 30 days post- procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Sirolimus-eluting balloon angioplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using Sirolimus Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel-eluting balloon angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using Paclitaxel Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting balloon catheter</intervention_name>
    <description>Sirolimus-eluting balloon catheter designed and produced by Acotec</description>
    <arm_group_label>Sirolimus-eluting balloon angioplasty</arm_group_label>
    <other_name>Sirolimus coated balloon catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting balloon catheter</intervention_name>
    <description>Paclitaxel-eluting balloon catheter (trade name:DHALIA)</description>
    <arm_group_label>Paclitaxel-eluting balloon angioplasty</arm_group_label>
    <other_name>Paclitaxel coated balloon catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old and ≤80 years old&#xD;
&#xD;
          -  Had lower extremity arterial occlusive diseases, and Rutherford classification is 2-5&#xD;
&#xD;
          -  SFA and/or popliteal artery had severe stenosis (stenosis degree ≥70%) or occlusion.&#xD;
&#xD;
          -  The length of target lesion less than 20 cm&#xD;
&#xD;
          -  Subject (or legal guardian) understands the study requirements and procedures and&#xD;
             provides written Informed Consent before any study tests or procedures are performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The plasma creatinine level is higher than 150 umol/L&#xD;
&#xD;
          -  Thrombolysis or thrombectomy is required&#xD;
&#xD;
          -  There are more than 2 lesion need to treat in the target vessel.&#xD;
&#xD;
          -  The patient had underwent lower-limb arterial surgery or thrombolysis on the target&#xD;
             limb within 6 weeks.&#xD;
&#xD;
          -  The target lesion had residual stenosis&gt;30% or flow-limit dissection after&#xD;
             pre-dilatation.&#xD;
&#xD;
          -  The patient had outflow less than 1 vessel&#xD;
&#xD;
          -  The lesion located in a stent.&#xD;
&#xD;
          -  Patient has a known allergy to aspirin, clopidogrel, heparin, paclitaxel, sirolimus or&#xD;
             contrast medium that cannot be adequately pre-medicated.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
          -  The subjects have participated in other drug property studies or device studies that&#xD;
             have not yet completed the main end point.&#xD;
&#xD;
          -  Patient has life expectancy of less than 12 months.&#xD;
&#xD;
          -  The investigator think the patient is not suitable for participation in the clinical&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guo Wei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guo Wei, MD</last_name>
    <phone>13910758706</phone>
    <email>pla301dml@vip.sina.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting balloon catheter</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

